Ignite Creation Date:
2025-12-25 @ 4:18 AM
Ignite Modification Date:
2026-03-06 @ 6:14 PM
Study NCT ID:
NCT03518320
Status:
TERMINATED
Last Update Posted:
2024-08-27
First Post:
2018-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Sponsor:
Taris Biomedical LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-01-02
Start Date Type:
ACTUAL
Primary Completion Date:
2019-12-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-12-11
Completion Date Type:
ACTUAL
First Submit Date:
2018-04-10
First Submit QC Date:
None
Study First Post Date:
2018-05-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-23
Last Update Post Date:
2024-08-27
Last Update Post Date Type:
ACTUAL